跳转至内容
Merck
  • Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.

Molecular cancer therapeutics (2015-06-17)
Yeon-Jin Kwon, Kevin Petrie, Boris A Leibovitch, Lei Zeng, Mihaly Mezei, Louise Howell, Veronica Gil, Rossitza Christova, Nidhi Bansal, Shuai Yang, Rajal Sharma, Edgardo V Ariztia, Jessica Frankum, Rachel Brough, Yordan Sbirkov, Alan Ashworth, Christopher J Lord, Arthur Zelent, Eduardo Farias, Ming-Ming Zhou, Samuel Waxman
摘要

Triple-negative breast cancers (TNBC) lacking estrogen, progesterone, and HER2 receptors account for 10% to 20% of breast cancer and are indicative of poor prognosis. The development of effective treatment strategies therefore represents a pressing unmet clinical need. We previously identified a molecularly targeted approach to target aberrant epigenetics of TNBC using a peptide corresponding to the SIN3 interaction domain (SID) of MAD. SID peptide selectively blocked binding of SID-containing proteins to the paired α-helix (PAH2) domain of SIN3, resulting in epigenetic and transcriptional modulation of genes associated with epithelial-mesenchymal transition (EMT). To find small molecule inhibitor (SMI) mimetics of SID peptide, we performed an in silico screen for PAH2 domain-binding compounds. This led to the identification of the avermectin macrocyclic lactone derivatives selamectin and ivermectin (Mectizan) as candidate compounds. Both selamectin and ivermectin phenocopied the effects of SID peptide to block SIN3-PAH2 interaction with MAD, induce expression of CDH1 and ESR1, and restore tamoxifen sensitivity in MDA-MB-231 human and MMTV-Myc mouse TNBC cells in vitro. Treatment with selamectin or ivermectin led to transcriptional modulation of genes associated with EMT and maintenance of a cancer stem cell phenotype in TNBC cells. This resulted in impairment of clonogenic self-renewal in vitro and inhibition of tumor growth and metastasis in vivo. Underlining the potential of avermectins in TNBC, pathway analysis revealed that selamectin also modulated the expression of therapeutically targetable genes. Consistent with this, an unbiased drug screen in TNBC cells identified selamectin-induced sensitization to a number of drugs, including those targeting modulated genes.

材料
货号
品牌
产品描述

Sigma-Aldrich
重组人表皮细胞生长因子, EGF, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
价格与库存信息目前不能提供
Sigma-Aldrich
异丙醇, ≥99.7%, FCC, FG
价格与库存信息目前不能提供
Sigma-Aldrich
2-丙醇, BioUltra, for molecular biology, ≥99.5% (GC)
价格与库存信息目前不能提供
Sigma-Aldrich
EGF 人, Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
价格与库存信息目前不能提供
Sigma-Aldrich
2-丙醇, electronic grade, 99.999% trace metals basis
价格与库存信息目前不能提供
Supelco
维生素A标准液 溶液, 100 μg/mL ± 25% (Refer to COA) (Ethanol with 0.1% (w/v) BHT), ampule of 1 mL, reference material, Cerilliant®
价格与库存信息目前不能提供
Sigma-Aldrich
2-丙醇, JIS special grade, ≥99.5%
价格与库存信息目前不能提供
Sigma-Aldrich
2-丙醇, anhydrous, 99.5%
价格与库存信息目前不能提供
Sigma-Aldrich
2-丙醇, for molecular biology, BioReagent, ≥99.5%
价格与库存信息目前不能提供
Sigma-Aldrich
人表皮生长因子,不含动物成分, EGF, recombinant, expressed in Escherichia coli, >97% (SDS-PAGE)
价格与库存信息目前不能提供
Sigma-Aldrich
EGF 来源于小鼠, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
价格与库存信息目前不能提供
Sigma-Aldrich
2-丙醇, SAJ first grade, ≥99.0%
价格与库存信息目前不能提供
Sigma-Aldrich
2-丙醇, 99.5%, HPLC grade
价格与库存信息目前不能提供
Sigma-Aldrich
EGF 来源于大鼠, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
价格与库存信息目前不能提供
Sigma-Aldrich
2-丙醇, suitable for HPLC
价格与库存信息目前不能提供
Sigma-Aldrich
EGF 来源于小鼠, Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC)
价格与库存信息目前不能提供
Sigma-Aldrich
2-丙醇, ACS reagent, ≥99.5%
价格与库存信息目前不能提供
Sigma-Aldrich
2-丙醇, HPLC Plus, for HPLC, GC, and residue analysis, 99.9%, poly coated bottles
价格与库存信息目前不能提供